GC
KRRO icon

Guggenheim Capital’s Korro Bio KRRO Stock Holding History

Guggenheim Capital’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Buy
14,097
+3,658
+35% +$40.3K ﹤0.01% 1545
2025
Q4 		$83.6K Buy
+10,439
New +$244K ﹤0.01% 1727

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Guggenheim Capital's KRRO Position: Q1 2026 in Review

Guggenheim Capital increased its Korro Bio (KRRO) stake by 35% in Q1 2026, buying an estimated $40.3K and bringing the position to 14,097 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1545.

Guggenheim Capital first reported a position in KRRO in Q4 2025 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold KRRO as of Q1 2026.

  • Guggenheim Capital held 14,097 shares of Korro Bio worth $160K as of Q1 2026.
  • Guggenheim Capital bought 3,658 Korro Bio shares in Q1 2026, an estimated $40.3K.
  • Korro Bio made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1545 holding.
  • Guggenheim Capital first reported a position in Korro Bio in Q4 2025 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Korro Bio as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.